What is the difference between Deslorelin and MK-677 (Ibutamoren)?

Deslorelin: Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production. MK-677 (Ibutamoren): Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take Deslorelin and MK-677 (Ibutamoren) together?

There is no specific, well-documented interaction rule for combining Deslorelin and MK-677 (Ibutamoren) in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Deslorelin or MK-677 (Ibutamoren)?

Deslorelin is currently research-stage and MK-677 (Ibutamoren) is research-stage. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

Deslorelin vs MK-677 (Ibutamoren)

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Deslorelin

Research-stage

Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.

Full profile

MK-677 (Ibutamoren)

Research-stage

Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation.

Full profile

	Deslorelin	MK-677 (Ibutamoren)
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH	Ibutamoren, Nutrobal, MK677, L-163,191
Evidence	Research-stage	Research-stage
Dosing range	50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset	10mg–50mg mg, once daily oral
Administration	Subcutaneous implant (veterinary), Subcutaneous injection	Oral (capsule/liquid)
Key side effects	Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability	Water retention, Increased appetite, Elevated fasting glucose (long-term), Fatigue (initial, transient)
Cited sources	2 references	2 references

Key differences

Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; MK-677 (Ibutamoren) — Oral (capsule/liquid).
Dosing units differ: Deslorelin is dosed in mcg, MK-677 (Ibutamoren) in mg — they operate at different scales.
Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; MK-677 (Ibutamoren) is once daily oral.

How each works

Deslorelin

Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.

MK-677 (Ibutamoren)

MK-677 binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and increase circulating IGF-1. Unlike peptide GHRPs it survives oral administration. Clinical trials demonstrate significant increases in GH pulsatility and IGF-1 without suppression of the endogenous GH axis, though long-term use raises glucose metabolism concerns.

Read the full Deslorelin profile Read the full MK-677 (Ibutamoren) profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.